Bluebird bio Inc (BLUE)

Precedente Chiudi:

$1.07

Aprire:

$1.1

Volume 24 ore:

1.65M

Capitalizzazione di mercato:

$206.23M

Reddito:

$21.73M

Utile/perdita netta:

$-91.17M

Rapporto P/E:

-1.0833

EPS:

-1.02

Flusso di cassa netto:

$-286.43M

1 W Prestazione:

+13.38%

1M Prestazione:

+7.28%

6M Prestazione:

-66.41%

1 anno Prestazione:

-73.18%

Intervallo 1D:

$1.06

$1.14

Portata 52W:

$0.851

$5.53

Bluebird bio Inc Stock (BLUE) Company Profile

Nome

Bluebird bio Inc

Settore

Healthcare (1213)

Industria

Biotechnology (696)

Telefono

339-499-9300

Indirizzo

60 Binney Street, Cambridge, MA

Dipendente

659

Cinguettio

@bluebirdbio

Prossima data di guadagno

2024-06-12

Ultimi documenti SEC

BLUE's Discussions on Twitter

Bluebird bio Inc Stock (BLUE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-04-28	Iniziato	JP Morgan	Overweight
2023-03-07	Iniziato	Robert W. Baird	Outperform
2022-08-05	Aggiornamento	Barclays	Underweight → Equal Weight
2022-08-02	Aggiornamento	Raymond James	Mkt Perform → Outperform
2022-04-06	Downgrade	Cowen	Outperform → Market Perform
2022-03-07	Downgrade	Barclays	Equal Weight → Underweight
2021-11-08	Reiterato	Barclays	Equal Weight
2021-11-08	Reiterato	Canaccord Genuity	Hold
2021-11-08	Downgrade	Goldman	Neutral → Sell
2021-11-08	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2021-11-08	Reiterato	RBC Capital Mkts	Sector Perform
2021-11-08	Reiterato	Wedbush	Neutral
2021-11-08	Reiterato	Wells Fargo	Equal Weight
2021-08-10	Downgrade	Canaccord Genuity	Buy → Hold
2021-08-10	Downgrade	Goldman	Buy → Neutral
2021-08-10	Downgrade	Wells Fargo	Overweight → Equal Weight
2021-08-10	Ripresa	William Blair	Mkt Perform
2021-08-09	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-07-01	Downgrade	Berenberg	Buy → Hold
2021-03-10	Aggiornamento	Mizuho	Neutral → Buy
2021-02-17	Downgrade	JP Morgan	Overweight → Neutral
2021-02-16	Downgrade	BofA Securities	Buy → Neutral
2021-02-16	Downgrade	Wedbush	Outperform → Neutral
2021-02-16	Downgrade	William Blair	Outperform → Mkt Perform
2020-12-09	Downgrade	Maxim Group	Buy → Hold
2020-11-11	Iniziato	Berenberg	Buy
2020-11-05	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-11-05	Downgrade	Barclays	Overweight → Equal Weight
2020-11-05	Downgrade	Stifel	Buy → Hold
2020-11-02	Aggiornamento	William Blair	Mkt Perform → Outperform
2020-10-20	Iniziato	Mizuho	Buy
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-03-27	Aggiornamento	Stifel	Hold → Buy
2020-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
2020-02-03	Ripresa	BofA/Merrill	Buy
2020-02-03	Aggiornamento	Evercore ISI	In-line → Outperform
2019-12-13	Aggiornamento	Oppenheimer	Perform → Outperform
2019-11-26	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-11-19	Downgrade	Evercore ISI	Outperform → In-line
2019-11-04	Aggiornamento	Wedbush	Neutral → Outperform
2019-10-01	Iniziato	Stifel	Hold
2019-08-12	Downgrade	William Blair	Outperform → Mkt Perform
2019-06-18	Aggiornamento	Maxim Group	Hold → Buy

Mostra tutto

Bluebird bio Inc Borsa (BLUE) Ultime notizie

bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well

Zacks Investment Research

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

bluebird (BLUE) Underperforms Industry YTD Amid Challenges

Zacks Investment Research

Is Bluebird Bio Stock a Buy?

The Motley Fool

Better Buy: Bluebird Bio Vs. Novavax

The Motley Fool

Is This Beaten-Down Stock a Good Acquisition Target?

The Motley Fool

Bluebird bio Inc Azioni (BLUE) Dati Finanziari

Bluebird bio Inc (BLUE) Reddito 2024

Bluebird bio Inc (BLUE) Reddito netto 2024

Bluebird bio Inc (BLUE) Flusso di cassa 2024

Bluebird bio Inc (BLUE) Utile per azione 2024

Bluebird bio Inc Azioni (BLUE) insider trading